Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors
- 1 July 2010
- book chapter
- review article
- Published by Springer Science and Business Media LLC in Current Topics in Microbiology and Immunology
- Vol. 347, 189-208
- https://doi.org/10.1007/82_2010_54
Abstract
The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this pathway have shown that pharmacological inhibition of PI3K in humans is feasible and overall well tolerated. Furthermore, there has already been clinical evidence of anti-tumor activity in patients with advanced cancer. The intensity and duration of PI3K inhibition required for an antitumor effect and the optimal pharmacodynamic biomarker(s) of pathway inactivation remain to be established. Preclinical and early clinical data support focusing on trials with PI3K inhibitors that are at a minimum enriched with patients with alterations in this signaling pathway. These inhibitors are likely to be more effective in combination with established and other novel molecular therapies.This publication has 91 references indexed in Scilit:
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Should individual PI3 kinase isoforms be targeted in cancer?Current Opinion in Cell Biology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004